Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 10Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Vomiting 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Prostatic Neoplasms 1Plasmacytoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1Blast Crisis 1

Interventions

Imatinib Mesylate 23Cyclophosphamide 18fludarabine 17fludarabine phosphate 13Busulfan 12Whole-Body Irradiation 11nilotinib 10Dasatinib 9thymoglobulin 8ponatinib 8Mycophenolic Acid 8Cytarabine 7Antilymphocyte Serum 7peginterferon alfa-2b 6Tacrolimus 6Cyclosporine 6Clofarabine 6Thiotepa 5Stem Cell Transplantation 4Sirolimus 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Alemtuzumab 4sargramostim 3Interferon-alpha 3Homoharringtonine 3Cord Blood Stem Cell Transplantation 3Bortezomib 3zileuton 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × auricularum × Clear all
NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
9 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡